GH Sports, the Leukemia & Lymphoma Society (LLS), and Be the Match & United Blood Services are launching the 2nd annual bone marrow registry and blood drive during blood cancer awareness month in September.
The founder of GH Sports, Greg Hind passed away in 2012 from a rare form of blood and bone marrow cancer, Acute Myeloid Leukemia (AML). Hind was always very supportive of the Leukemia & Lymphoma Society’s team in training and other community-based programs. To honor his support, together, with Be the Match, United Blood Services & LLS, GH Sports is hosting the 2nd annual bone marrow registry and blood drive in addition to offering a Blowout Sale with up to 80% off of everything in store.
This event will take place on Saturday, Sept. 13 from 9a.m.-6p.m. with a brief program with media availability for interviewers. GH Sports will host this event in the parking lot at 3765 S. Higuera, Suite 100.
GH Sports (Greg Hind Sports), formerly known as Hind Performance wear, designs, tests, sews, and distributes quality run, cycle, swim, triathlon, and fitness apparel from its San Luis Obispo, CA retail and manufacturing facility. The company was started in 1969 when Greg Hind developed and patented the first ever water polo protective headgear, called G-H Ear Guard, and continues today with the same focus to develop technical, quality apparel and accessories that perform and last. GH Sports is open six days a week; Monday – Friday 10a.m. – 5:30p.m. and Saturday 10a.m. – 5p.m.
Blood cancers are the third leading cause of cancer death. Approximately every four minutes one person in the United States is diagnosed with a blood cancer. The Leukemia & Lymphoma Society (LLS), is the world’s largest voluntary health agency dedicated to finding cures and providing access to treatments for blood cancer patients.
Over the last 60 years, LLS has invested almost $1 billion in research to advance therapies and save lives. Many are surprised to learn that LLS research grants have helped advance many of the most promising advances in cancer therapies, including targeted therapies and immunotherapies.
LLS is changing the paradigm of philanthropy, driving research in areas of unmet medical need, and helping to bridge the gap between academic discovery and drug development. We do that by creating partnerships with universities and biotechnology and pharmaceutical companies to provide funding across the continuum from basic research through clinical trials.
Therapies that don’t make it to patients can’t help them. A key LLS priority is ensuring access to quality, affordable, coordinated care for blood cancer patients through legislative advocacy and patient services.
Be The Match, operated by the National Marrow Donor Program, is the world’s largest and most diverse registry of potential marrow donors. Be The Match connects patients to life-saving donors for a cure. For patients with diseases like leukemia, lymphoma and sickle cell anemia, a marrow or umbilical cord blood transplant may be their only life-saving treatment.